Overcoming barriers to implementing new guideline-directed therapies for chronic kidney disease

By sjmartinez • October 21, 2022

Nee R, Yuan CM, Narva AS, Yan G, Norris KC. Overcoming barriers to implementing new guideline-directed therapies for chronic kidney disease. Nephrol Dial Transplant. 2022 Oct 20:gfac283. doi: 10.1093/ndt/gfac283. Epub ahead of print. PMID: 36264305.

Tags: cardiovascular disease, Chronic kidney disease, diabetes mellitus, glucagon-like peptide-1 receptor agonist, Nephrology, nonsteroidal mineralocorticoid receptor antagonist, Publications, sodium-glucose cotransporter-2 inhibitor

HEV-Targeted Antibody-Drug Conjugate Promotes Long-Term Cardiac Allograft Acceptance

Che Y, Yamamura Y, Jung S, Sabiu G, Kondengadan SM, Lucia SE, Song Y, Byun H, Li X, Seelam AJ, Yamamura M, Inoue Y, Zhao[...]

Clinical practice pattern of management of plasma cell dyscrasia for kidney transplant candidates and recipients in the United States

Boppana S, Blosser CD, Webber AB, Gupta G, Singh N, Master S, Parasuraman R, Campagnaro EL, Java A, Sprangers B, Bhasin-Chhabra B, Lum EL, Khirfan[...]

Prevalence and dynamics of HLA Donor-Specific antibodies in Simultaneous Liver-Kidney transplantation

Zhang Q, Pulido MA, Soltero S, Butler C, Lum E, Abdalla B, Kendrick E, Yabu JM, Pham PT, Bunnapradist S, Veale J, Gritsch AH, Danovitch[...]